<p> European regulators will clamp down on “pay-for-delay” deals in the pharmaceutical sector this month, fining Denmark's Lundbeck, India's Ranbaxy and seven other generic drug manufacturers for limiting access of cheaper products to the market.<br /><br /></p>.<p>Following an inquiry launched in 2009, the European Commission, the EU's anti-trust regulator, will impose a "significant" fine on Lundbeck and lesser fines on Germany's Merck KGaA and seven smaller drug firms when it announces the sanctions later this month, two officials said.<br /><br />The Commission can fine a company up to 10 per cent of its global revenue for breaching EU antitrust laws, which in Lundbeck's case would be up to 240 million euros.<br />Officials gave no indication of the precise size of the fines apart from to say it will be sizeable in Lundbeck's case.</p>
<p> European regulators will clamp down on “pay-for-delay” deals in the pharmaceutical sector this month, fining Denmark's Lundbeck, India's Ranbaxy and seven other generic drug manufacturers for limiting access of cheaper products to the market.<br /><br /></p>.<p>Following an inquiry launched in 2009, the European Commission, the EU's anti-trust regulator, will impose a "significant" fine on Lundbeck and lesser fines on Germany's Merck KGaA and seven smaller drug firms when it announces the sanctions later this month, two officials said.<br /><br />The Commission can fine a company up to 10 per cent of its global revenue for breaching EU antitrust laws, which in Lundbeck's case would be up to 240 million euros.<br />Officials gave no indication of the precise size of the fines apart from to say it will be sizeable in Lundbeck's case.</p>